Korea’s Celltrion Move For Remsima Bridging Trial In Germany Seen As Flight Path To U.S. 2014 Filing
This article was originally published in PharmAsia News
South Korea’s Celltrion has received a nod from Germany’s Paul Ehrlich Institut for a bridging study of the Remsima biosimilar of Johnson & Johnson’s tumor necrosis factor inhibitor Remicade (infliximab), a step crucial to hopes of filing for approval in the United States in early 2014.
You may also be interested in...
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.
While the South Korean pharma sector is ultimately targeting US and European markets in its longer-term expansion drive, it is for now trying to build up wider relations with Middle East countries with a little top-level political help.